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Abstract O-glycosylation is a widely occurring posttransla-
tional modification of proteins. The glycosylation status of a
specific site may influence the location, activity and function
of a protein. The initiating enzyme of mucin-type O-glycosyl-
ation is UDP-GalNAc:polypeptide GalNAc transferase
(ppGalNAcT; EC 2.4.1.41). Using electron-transfer dissocia-
tion mass spectrometry, ppGalNAcT from the snail
Biomphalaria glabratawas characterized regarding its ability
to glycosylate threonine and serine residues in different pep-
tide sequence environments. The preferences of the snail
enzyme for flanking amino acids of the potential glycosylation
site were very similar to vertebrate and insect members of the
family. Acceptor sites with adjacent proline residues were
highly preferred, while other residues caused less pronounced
effects. No specific O-glycosylation consensus sequence was
found. The results obtained from synthetic peptides were in
good correlation with the observed glycosylation patterns of
native peptides and with the order of attachment in a multi-
glycosylated peptide. The snail enzyme clearly preferred thre-
onine over serine in the in vitro assays. No significant differ-
ences of transfer speed or efficiency could be detected using a
mutant of the enzyme lacking the lectin domain. This is the
first characterisation of the substrate specificity of a member
of the ppGalNAcT family from mollusc origin.
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Introduction
Glycosylation plays an important role in several types of
recognition processes ranging from fertilization and develop-
ment to pathological events and cell death. In earlier times of
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glycobiology the role of O-glycans was merely seen in the
influence of physical parameters, like ensuring protein stabil-
ity and tertiary structure, serving as “stalks” in membrane
bound receptors and providing the basis for rigid conforma-
tion of the polypeptide backbone; the more specialized func-
tions had been allocated to N-glycans. In the meantime it has
been shown, that O-glycans can be also relevant for the fine
tuning of biological processes, such as modulation of en-
zyme activity, they may act as signal molecules or sorting
determinants [1–5]. Mucin-type O-glycosylation is the
most frequent type of O-glycosylation, present in all kinds
of animals containing an N-acetylgalactosamine as the link-
age sugar to a hydroxy amino acid of a peptide [6–8]. This
precursor is further elongated by adding galactoses, N-
acetylglucosamines, N-acetylgalactosamines, fucoses, sial-
ic acids and other sugars depending on the organism, tissue
and developmental stage. The first enzyme involved in the
biosynthesis of these O-glycans is a member of an evolu-
t i o n a r i l y h i g h l y c o n s e r v e d f am i l y o f UDP -
GalNAc:polypeptide GalNAc transferases (ppGalNAcTs,
[EC 2.4.1.41]), which transfer the GalNAc residue from
UDP-GalNAc to a serine (Ser) or threonine (Thr) of a
polypeptide chain. The family members share a common
structure consisting of a short transmembrane domain, a
stem region, a Gal/GalNAc motif, a manganese binding site
and, quite commonly, a ricin-like lectin domain. Small
differences in structure seem to be related to tissue distri-
bution and acceptor specificity.
In humans 20 representatives of this enzyme family have
been found, 19 in rodents, 14 in Drosophila melanogaster, 9 in
Caenorhabditis elegans and several in other organisms [9–11].
The large number of seemingly redundant homologues of the
same enzyme in one organism indicates that it requires a reliable
backup system. In most of the experiments in mice the loss of a
single GalNAcT-gene caused no obvious phenotype (for a re-
view see 10). However, in Drosophila melanogaster
ppGalNAcTs have been shown to be essential for viability [12].
The ppGalNAcTs have been clustered into groups and
subgroups by their primary structure [10]. While N-
glycosylation is restricted to Asn-residues within the consen-
sus sequence Asn-X-Ser/Thr, for mucin-type O-glycosylation
no strict amino acid sequence can be determined. However, a
number of studies on vertebrate enzymes demonstrate that the
different groups and subgroups favour specific amino acids
close to the glycosylation site of the acceptor peptide. Further-
more these groups differ also in their ability to transfer
GalNAc-residues to already glycosylated acceptor substrates
and their expression levels vary for different tissues.
Molluscs are highly successful in survival, are able to adapt
to changing environments and are intermediate hosts of some
parasites. They combine glycosylation features of mammals,
worms and insects which makes them an interesting model for
studies of biosynthetic pathways, in particular glycosylation
processes. ppGalNAcT from Biomphalaria glabrata
(GenBank: KC18251), so far the only cloned and character-
ized glycosyltransferase from mollusc origin, is a 600 amino
acid type II membrane protein containing all the above men-
tioned structural domains [13]. It is a member of group Ib
being a typical T2 enzyme [10], with a pH optimum at 6.0–
6.5, dependence on divalent cations and it is able to glycosy-
late non- as well as multi-glycosylated acceptor peptides [13].
Here we present a detailed evaluation of the snail
ppGalNAcT donor and acceptor preferences and elucidate
the order and position of the glycosylated amino acids in case
of multi-glycosylation. Furthermore, the influence of the lec-
tin domain on the specificity of the snail enzyme is revealed.
Material and methods
Materials Spodoptera frugiperda cells (Sf9, ATCC CRL-
1711) were cultivated in IPL41 medium (SAFC Biosciences,
St. Louis, USA) containing yeast extract, a lipid mixture
supplemented with 10 % fetal calf serum, at 27 °C [14].
Acceptor peptides were obtained from Cellmano Biotech
Co., Ltd., Shanghai, China (Table 1).
Expression of ppGalNAcT from Biomphalaria glabrata The
enzyme, ppGalNAcT, without cytoplasmic tail and transmem-
brane domain (amino acid 1–26) was expressed and purified
exactly as in [13]. A further truncated version,ΔppGalNAcT,
omitting the complete lectin domain (lacking amino acid 477–
600) was obtained in the same way. Protein concentrations
were determined by the Micro-BCA protein assay (Pierce,
Bonn, Germany) with bovine serum albumin as the standard.
ppGalNAcTactivity assay The enzyme activity of ppGalNAcT
and ΔppGalNAcT was determined in 20 μl reaction mixture
containing 50mMMES (2-(N-morpholino)ethanesulfonic acid),
pH 7.0, 10 mM MnCl2, 2 mM UDP-GalNAc (Sigma-Aldrich,
Vienna, Austria), 10 nmol acceptor peptide (Cellmano Biotech
Co., Ltd., Shanghai, China) and 2 μl enzyme solution
(ppGalNAcT or ΔppGalNAcT, protein concentrations
5.0 μg/ml) at 37 °C for 90 min.
For determination of donor specificity UDP-Gal, UDP-
GlcNAc, GDP-fucose, UDP-xylose, UDP-glucuronic acid
(all from Sigma-Aldrich, Vienna, Austria) and CMP-
neuraminic acid (Jennewein Biotechnologie GmBH, Germa-
ny) were used instead of UDP-GalNAc. For time courses the
standard assay was conducted for 30 h and aliquots were taken
at 1, 2, 4, 6, 8, 23, 26 and 30 h. For determination of the
position of the transferred GalNAc-residues within the pep-
tide, incubation was carried out with Muc1a, Muc1a’,
Muc5Ac and Muc2, respectively (for sequences see Table 1),
for 24 h analogously to the standard assay with additions of
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10 nmol UDP-GalNAc and 2 μl of enzyme solution after 4, 8
and 20 h.
Each assay was carried out at least in duplicate with appro-
priate controls.
Analysis of enzyme activity Quantitative analysis was per-
formed by HPLC on a reversed phase C18 column (4.6×
250 mm, 5 μm, Thermo Scientific, Vienna, Austria) in
0.5 % trifluoroacetic acid in water, applying a linear gradient
from 15 to 25 % of eluent (0,1 % trifluoroacetic acid in
acetonitrile) in 20 min at a flow rate of 1 ml/min with a
detection at 220 nm. All quantitative values were calculated
from the area of HPLC patterns.
Preparation of mono-glycosylated acceptors Mono-glycosyl-
ated Muc2 and Muc5Ac were obtained using the standard
assay conditions with 2 h of incubation time, followed by
preparative runs on HPLC exactly as for the quantification
analysis. The peak containing the mono-glycosylated peptide
was collected manually.
Matrix assisted laser desorption ionisation – time of flight
(MALDI-TOF) mass spectrometry MALDI-TOFMS analysis
was carried out on an Autoflex Speed MALDI-TOF (Bruker
Daltonics, Germany) equipped with a 1000 Hz Smartbeam.II
laser in positivemode usingα-cyano-4-hydroxycinnamic acid
as matrix (1 % in 65 % acetonitrile solution). For crystalliza-
tion 1 μl of an 1:40 dilution of the samples was spotted on the
plate, air dried, covered by 1 μl of matrix solution and again
air dried. Spectra were processed with the manufacturer’s
software (Bruker Flexanalysis 3.3.80).
E l e c t ro n Tr a n s f e r D i s s o c i a t i o n ( ETD ) ma s s
spectrometry ppGalNAcT activity assay solutions were puri-
fied via C-18 SPE cartridges (25 mg, Thermo Scientific).
Briefly, the cartridges were equilibrated with 500 μl methanol,
500 μl 65 % acetonitrile and washed twice with 500 μl 0,1 %
formic acid. Sample was applied, washed twice with 500 μl
0,1 % formic acid and Muc peptide was eluted with 65 %
acetonitrile. For direct infusion ETD-MS, the samples were
vacuum-dried and redissolved in 50 % acetonitrile.
Muc peptides were directly infused into a Bruker amaZon
speed ETD ion trap using a Hamilton syringe at a flow rate of
2 μl/min. The mass spectrometer was operated in Manual
MS(n) mode with ETD as fragmentation mode. Triply or four
times charged precursors ions were measured with the follow-
ing settings: ICC target 200000, maximum accumulation time
10 ms, isolation width 4 amu, ETD reagent time 60–100 ms.
Data were recorded for about 10–15 min for every glycopep-
tide form and analysed with Bruker’s Data Analysis 4.0.
Average mass spectra were generated using the SNAP peak
finder algorithm and exported to Bruker’s BioTools 3.2. Via
the Sequence Editor, Muc peptide sequences with additional
GalNAc modification(s) on every possible site (Ser or Thr)
were generated and sent to BioTools. Theoretical peptide
fragment masses (c- and z-type ions) were calculated for every
possible glycopeptide form and compared to measured frag-
ment masses. The identification of fragment ions, specific for
a certain GalNAc modification site enabled us to illuminate
the different glycosylation sites on the different Muc peptide
species [15, 16].
Results
Determination of donor specificity The donor specificity of
snail ppGalNAcT was investigated using standard assay con-
ditions with the acceptor substrates Muc2 and Muc5Ac
Table 1 Acceptor peptides used in this study
Name Sequence
Muc1a APPAHGVTSAPDTRPAPGC

























CHT 23 PSSSPISSSSSVSPSPSPSGSQSK (analog of Muc2 with
Thr changed to Ser)
CHT 24 APPAHGVSTAPDTRPAPGC (analog of Muc1a with
an interchange of Thr and Ser)
a For clarity in the synthetic peptides CHT 1 – CHT 22 the Thr residue is
bold and the amino acid residues which are varied are underlined
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peptide as well as the corresponding mono-glycosylated pep-
tides and the nucleotide sugars UDP-Gal, UDP-GlcNAc,
GDP-fucose, UDP-xylose, UDP-glucuronic acid and CMP-
neuraminic acid instead of UDP-GalNAc. In none of these
experiments any addition of a sugar was observed byMALDI
(data not shown). Obviously, the snail enzyme is strictly
specific to UDP-GalNAc. In contrast, the human
ppGalNAcT2 has been found to utilize also UDP-Gal [17].
Localisation of GalNAc residues Previously we have shown
by MALDI-TOF analysis that the snail ppGalNAcT transfers
up to eight GalNAc residues to Muc2 peptide [13]. In order to
obtain more information about the sites and a possible order of
glycosylation, we analysed a large scale incubation of Muc2
with ESI-ETD-MS/MS. Muc2 forms with 1–8 GalNAc resi-
dues were selected as precursors for the ETD reaction and
analysed consecutively. Due to the heterogeneity of the higher
glycosylated Muc2 forms (especially the one with 5
GalNAcs), conclusion only about the major glycoform could
be drawn. Nevertheless, an order of glycosylation of the
different sites of modification by ppGalNAcT could be
deduced.
Thr-15 was clearly identified as the transferase’s first
choice. With three Pro residues at positions −1, +1 and +3,
this glycosylation site displays the previously published pre-
requisites for an ideal O-glycosylation site [18] (“+” or “−”
refers to residues that are N-terminal or C-terminal to a hy-
droxyl amino acid. The number reflects the distance from the
hydroxyl amino acid). The second GalNAc-residue was trans-
ferred to Thr-2 or Thr-13. Both have two Pro residues in close
proximity. For Thr-2 they are in position −1 and +3, whereas
for Thr-13 Pro is located at +1 and +3. Thr-17 with Pro in −1
and +1 is the subsequent glycosylation site, almost equal to
Thr-10, which has no Pro anywhere close. Thr-19, with two
Pro at −1 and −3, but none on the other side, is next target,
followed by Thr-8 and Thr-4 (Table 2, Fig. 1). Glycosylation
at Thr-21 was detected in a low amount and only in the form
with 8 GalNAc residues, and only when no GalNAc was
present linked to Thr-19. Thus, even with 14 Thr residues
present in Muc2, only 9 potential glycosylation sites were
identified, of which a maximum of 8 were in use, since Thr-
19 and Thr-21 were never glycosylated in the same peptide
(Fig. 1). GalNAc residues on directly adjacent residues were
never detected. Glycosylation sites were always separated by
at least one amino acid.
Also in Muc5Ac, Muc1a and Muc1a’ (which is a shorter
version of Muc1a) the glycosylation sites where determined.
In the sequence of Muc5Ac Ser-5 was the preferred acceptor
site probably due to surrounding Pro residues at position −1, +
1 and +3. With longer incubation times up to four GalNAc
residues could be attached. For Muc1 and Muc1a’ only the
Thr residues were identified as possible glycosylation sites
(Thr-8 and Thr-5 respectively). No GalNAc attachment to Ser
could be observed. After an interchange of Thr and Ser in the
sequence of Muc1a (Thr-8 →Ser-8 and Ser-9 →Thr-9), the
peptide (CHT 24) was no longer an acceptor for snail
ppGalNAcT. CHT 23, an analogue of Muc2 with all Thr
residues changed to Ser residues, had a drastically reduced
GalNAc transfer rate. While on Muc2 peptide 8 GalNAc
residues could easily be attached, only four GalNAc residues
could be transferred to CHT 23, even after the longest incu-
bation time.
Determination of acceptor specificity with synthetic peptides
In order to investigate the optimal amino acid sequence close
to a potential O-glycosylation site, 22 synthetic variants of a
good acceptor peptide with one single Thr and no Ser were
tested (Table 1). The model acceptor peptide was designed
based on earlier studies of human ppGalNAcT2 [18–21]. Our
variation study included only three amino acids upstream and
downstream from the glycosylation site, still the length of the
chosen peptide was 17 amino acids in total, in order to avoid
activity reductions due to too small chains. About 30 % of
Muc1a peptide (19 amino acids) was converted into GalNAc-
Muc1a in the standard incubation assay, whereas Muc1a’
peptide, a shorter version of Muc1a with 11 amino acids,
was converted to only 6 % (Fig. 2).
The central amino acid of the model peptide was a Thr
surrounded by four Pro residues in position −3, −1, +1 and +3
and two Gly at −2 and +2. These Pro and Gly residues were
changed, while the five amino acids at the N- and at the C-
terminus, respectively, were kept the same for all peptides.
Glycosylated products of the standard incubation assay were
analysed by MALDI-TOF MS and quantified by HPLC. The
acceptor peptides were sorted into 4 groups according to
acceptor quality (Table 3): group 1 – complete glycosylation
within the time of the standard assay; group 2 – over 50 %;
group 3 – 5–49 %; and group 4 - only traces were glycosyl-
ated. For those peptides which were completely converted
within the standard conditions (CHT 1, CHT 3, CHT 9,
CHT 10, CHT 11, CHT 12, CHT 13), the experiment was
repeated with a quarter of the previous amount of enzyme.
This revealed that for three of them (CHT 3, CHT 9, CHT 12)
Table 2 Ranking of Thr
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the change of one Pro (position −1: Pro→His; +1: Pro→Glu;
+3: Pro→Tyr) enhanced the quality of the acceptor, all the
others slightly reduced incorporation compared with CHT 1.
Changing the Gly in position +2 to Arg (CHT 11) did not
affect the incorporation while the change to another basic
amino acid (His) led to a drastic decrease (CHT 5). Only a
moderate decrease was seen changing at −2 Gly→Val (CHT
13) or at −1 Pro→Val (CHT 2). Combining all changes with
moderate effect (His-Val-Val-Thr-Glu-Arg-Tyr, CHT 15), ac-
tivity was completely abolished.
A similar example for a poor combination is CHT 6.
Changing both Pro to Tyr at +3, which alone increased activity
(CHT 3), and Pro to Val at −1, which alone only moderately
decreased activity (CHT 2) resulted in a significant decrease
of acceptor quality (CHT 6).
But also an increase of activity could be observed by
combining some changes that decreased acceptor activity
previously: a change of Gly→Ala at +2 gives a rather weak
acceptor (CHT 22). But this change together with Gly→Phe at
−2 and Pro→Val at −1 (CHT 18) increased acceptor quality. If
there was an additional change of Pro→Asp at −3 a further
activity increase was detected (CHT 16) while Pro→Val or Ile
at −3 had a less pronounced effect (CHT 20, CHT 19), yet,
was still better than Ala alone (CHT 22). When the Pro→Asp
change at −3 was combined with Ala at +2 and Phe at −2 OR
Val at −1 (CHT 17, CHT 21), the activity was less than for Ala
alone (CHT 22).
The −1 position was found to be especially sensitive to
changes. There, Pro→Val yielded in moderate reduction
(CHT 2) while Pro→Ile, Leu or Phe resulted in a strong
decrease (CHT 7, CHT 14) or complete abolishment of activ-
ity (CHT 8). However, the change of Pro to Ile at +1 resulted
only in a slightly weaker acceptor quality (CHT 10).
Taken together, the results obtained with the synthetic
peptides, Pro residues in −3, −1, +1 and +3 favoured GalNAc
addition, but other amino acids may be also present (−3: His,
Asp; −2: Val, Phe; −1: Val; +1: Glu, Ile; +2: Arg, Ala, His; +3:

















































































































Fig. 1 Annotated ETD-MS/MS spectrum. Muc2 peptide with eight
GalNAc residues [M+4H]4+ at 1018 m/z was taken as a precursor for
the ETD reaction. Analysis of the fragment ionmasses revealed the amino
acids carrying a GalNAc modification. Two different forms (indicated
with ° and *), slightly differing in modification site of the most C-terminal
GalNAc were identified (see insert). Fragment ions marked with ° or *













Fig. 2 Incorporation rate of GalNAc residues into native acceptor
peptides
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amino acid at a specific position except that some amino acids
completely prevented transfer (−1: Ile, Leu, Phe; +3: Lys).
Generally, we found that the more amino acids we changed in
the acceptor peptide that were previously identified as “ideal”
for vertebrates, the less efficient the acceptor became.
Evaluation of glycosylation sites of native acceptors
ETD-MS/MS, which had been already applied by Yoshimura
[22] to identify the glycosylation sequence carried out by
human ppGalNAcT3 on Muc5Ac, was used for revealing
the incorporation of GalNAc into the native acceptors Muc1a,
Muc1a’, Muc2 and Muc5Ac. The preferred glycosylation
sites correlated well with the preferences shown above. Thr-
8 of Muc1a is flanked by the sequence His-Gly-Val upstream
and Ser-Ala-Pro downstream, which is for sure a good variant.
In contrast, Thr-13 is located between Ala-Pro-Asp and Arg-
Pro-Ala, which is not surprisingly an unfavourable
combination.
Shortening of the total chain (Muc1a’) did not change the
preference but reduced the transfer rate. Changing the Thr to
Ser in the previously preferred glycosylation site of this pep-
tide abolished its acceptor qualities totally (CHT 24). This is
surprising as a Ser residue in a similar good neighbourhood
Thr-Thr-Pro-Ser-Pro-Val-Pro is the enzyme’s first choice in
Muc5Ac.
The first sites of incorporation into Muc2 can be predicted
by the surrounding environment. Thr-15 with Pro in −1, +1,
and +3 was the preferred acceptor site followed by Thr resi-
dues with less Pro residues in ideal positions (see above). The
weakest acceptor was Thr-21 with only one Pro at −3.
An already glycosylated Thr in −2 position or in +2 posi-
tion seemed to enhance further glycosylation. This was not the
case for Thr-21. A previous glycosylation of Thr-19
prohibited any glycosylation at Thr-21 as we never found
glycosylated products on both of these sites.
A big exception to all these empirical rules was the fast
glycosylation of Thr-10 despite the lack of Pro in close
neighbourhood. There is a Val at +2 and an already
Table 3 Peptides listed by their quality as acceptors for snail
ppGalNAcT. For clarity only those amino acids are given that are
changed compared to the model peptide. Group 1: very good acceptors
(95–100% of acceptor conversion using standard conditions), group 2
moderate acceptors (50–94% conversion), group 3: weak acceptors (5–
49% conversion), group 4: incorporation less than 5%
a Ideal acceptor peptide for vertebrate ppGalNAcT2 according to [18]
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glycosylated Thr at +3; the rest are not glycosylated Thr
residues. The already glycosylated Thr may be the reason of
the conversion of the sequence into an attractive acceptor.
Influence of the lectin domain on substrate specificity
All native and synthetic peptides were also tested using an
enzyme variant devoid of the lectin domain (ΔppGalNAcT).
Overall the specificity for the synthetic acceptors with one
glycosylation site was similar. No differences were observed
for group 1 and group 4. In group 2 and 3 a change in −2
position had more influence on the activity towards an accep-
tor without lectin domain than on the complete enzyme. CHT
13 with Gly→Val in position −2 turned out to be a weaker
acceptor for ΔppGalNAcT. Only 46 % incorporation was
detected by the enzyme without lectin domain compared to
100 % transfer by the enzyme containing the lectin domain.
While Phe at that position often slightly increased the transfer
(CHT 16: 70→80 %, CHT 18: 70→75 %).
For the native substrates Muc2 and Muc5Ac we performed
a time course with the complete enzyme and with
ΔppGalNAcT. Samples were analysed by HPLC and
MALDI-TOF MS after 1, 2, 4, 6, 8, 23, 26 and 30 h. Both
enzyme variants incorporated the same number of GalNAc
residues (maximum 8 in Muc2 and 4 in Muc5Ac) and exhib-
ited the same incorporation rate. A similar result was obtained
for CHT 23 (maximum 4 GalNAc residues)., which is the Ser-
version of Muc2. Remarkably, there was no statistical signif-
icant difference in the transfer rate comparing the enzyme
variants with and without lectin domain (Fig. 3).
Discussion and conclusion
Despite a considerable phylogenetic distance, the recently
identified ppGalNAcT from the snail Biomphalaria glabrata
displays homology to human ppGalNAcT, especially to
ppGalNAcT2 (74 % positives with 58 % identity according
to NCBI blast analysis). Here, we aimed at a characterization
of the donor and acceptor substrate specificity to find out
about parallels or differences between snail ppGalNAcT and
human ppGalNAcT2, which is the only crystallised [37] and
the best characterised member of the ppGalNAcT2 homologs.
The core regions of our synthetic peptides used in this
study were variants of Pro-Gly-Pro-Thr-Pro-Gly-Pro, which
had been identified by Gerken et al. to be an ideal acceptor
peptide for human ppGalNAcT2 [18]. In order to overcome
the activity reduction seen with too small chains we added 5
amino acids on both ends of this core, resulting in peptides
containing 17 amino acids.
In previous studies on vertebrate ppGalNAcT2 and on the
Drosophila ortholog PGANT2 the enhancing activity of Pro
residues close to the glycosylation site had been determined
[19, 23–25]. Especially the −1 position was found to be
particularly relevant [20]. Charged amino acids in general
decreased the activity, while Ser, Thr, Ala and Gly residues
seemed to be acceptable in most of the positions. Neither
strong hydrophobic nor hydrophilic amino acids seemed to
be necessary. Large, especially aromatic side chains abolished
activity [19, 20, 24, 26]. On the basis of the evaluation of a
large set of O-glycosylation sites of vertebrate proteins,
Elhammer et al. developed an algorithm for the prediction of
probable glycosylation sites. The accuracy of the method is
about 75–85 % [19, 27].
In general, the results found for vertebrate ppGalNAcTs
correlate with the data we received for the Biomphalaria
glabrata enzyme [28–31]. Only small differences were de-
tected. At +2 position Gly and Ala had been identified as the
most favourable amino acids for the human ppGalNAcT2 and
an in vivo system using COS7 cells [18, 20]. The snail enzyme
clearly preferred Gly and Arg but was less in favour for Ala in
this position. An enhancement by Tyr at +3 was found for
human ppGalNAcT1, but not for human ppGalNAcT2 or
Drosophila PGANT2 [18, 25], albeit snail ppGalNAcT2 ac-
tivity was elevated by Tyr at +3. Similar to human
ppGalNAcT2 Phe, Ile, Leu decreased activity significantly
but Val was not that bad for the snail enzyme as it had been
described for the human one [18]. Similar to human
ppGalNAcT2 Pro at −1 and +3 was very important, while
Glu at +1 was less supportive for the human than for the snail
enzyme. His at −3 prevented activity of human ppGalNAcT2,
however, the snail enzyme was enhanced by this modification.
Lys at +3 was inhibitory for snail ppGalNAcT2.
Studying the order of O-glycosylation of Muc5Ac, we
found that the snail ppGalNAcT2 used Ser-5 rather than
Thr-9 as the first glycosylation site which is in contrast
to human ppGalNAcT2 [31]. This is surprising, as in all
other cases the snail enzyme clearly preferred Thr over
Ser residues, which is in accordance with other
ppGalNAcT2s [17, 19]. However, an early study on
ppGalNAcTs using a preparation from bovine colostrum
found that in vivo the preference may be different as
compared to the in vitro requirements [26].
As soon as the acceptors were already glycosylated, the
situation became even more complex. While the above
mentioned preferences for neighbouring amino acids were
still visible, the glycosylation status of adjacent Thr resi-
dues influenced the choice of attachment sites. Similar to
the human ppGalNAcT2 the snail enzyme did not require
previous glycosylation [31]. We also did not observe a
preference for C-terminally placed GalNAc-O-Thr residues
as has been shown for human ppGalNAcT2 [32]. In
agreement with earlier results from vertebrates [33–36],
glycosylation of potential glycosylation sites next to an
already occupied site was not detected. Therefore, the snail
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enzyme is definitely not a “finishing” enzyme like human
ppGalNAcT7, ppGalNAcT10 or ppGaNAcT15 which add
the final GalNAc residues to already highly glycosylated
acceptors, even in neighbouring positions. Thus, one may
speculate that the snail genome harbours further
ppGalNAcT homologs.
In comparison with all other so far analysed
ppGalNAcT2s from vertebrates and also from Drosoph-
ila melanogaster, the enzyme from Biomphalaria
glabrata displays similar preferences for flanking amino
acids of a potential glycosylation site. It has a broad
specificity for non-glycosylated as well as glycosylated
acceptor substrates. Thr is preferred over Ser. but pre-
dictions about glycosylation of a specific site must be
made with caution.
Several studies have been performed discussing the
influence of the lectin domain on the glycosylation
behaviour. It was shown that the lectin domain was not
necessary for catalytic activity of human ppGalNAcT2 but
shifts in the preferred sites of glycosylation and higher
densities of glycosylation may occur [30–32, 37, 38]. For
the snail enzyme we did not observe remarkable differ-
ences of transfer for acceptors with one single glycosyl-
ation site as well as for acceptors with multiple glyco-
sylation sites, neither in speed of incorporation nor in
the final number of attached GalNAc residues.
Taken together, this first thorough study of the sub-
strate specificity of a ppGalNAcT from a snail reveals
remarkable similarities to the transferases from verte-
brates and insects. One can speculate that also molluscs
contain more than one type of ppGalNAcT, like it has
been shown for the other so far analysed species. Con-
sidering several millions of years of separate evolution,
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Fig. 3 MALDI-TOF ([M+ Na]+) analysis of the transfer of GalNAc
residues using Muc5Ac, Muc2 or CHT 23 as acceptor peptide. Acceptor
peptide without incubation (a,d,g); 8-h-incubation with ppGalNAcT
containing the lectin domain (b,e,h); 8-h-incubation with ppGalNAc
without the lectin domain (c,f,i). The numbers indicate the incorporated
GalNAc residues
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suggests a highly important common function or set of
functions of protein O-glycosylation.
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